DebbieKwonMD

Excited to announce that after 4 rejections and countless moments of despair and almost giving up, I received my first Notice of Award for my first R01! Huge thanks to @WilsonTangMD for incredible mentorship, CIRC, and our HVTI leadership, supporting and fostering innovation.

Night to remember with friends and colleagues @EACVIPresident @iamritu @DebbieKwonMD @VDelgadoGarcia Thank you for an outstanding conference where science is fun ! @CCFcards @CleClinicMD

@DebbieKwonMD @CCFcards stress CMR for further risk evaluation in the ischemia trial. Stress CMR an invaluable tool that is underutilized .

#EHJCVI 🔍 How is cardiovascular imaging reshaping VHD trials? This new review explores the expanding role of CV imaging across RCTs in different VHD, highlighting its impact on design, endpoints, and translation into clinical practice🫀📊 Read more 👉 doi.org/10.1093/ehjci/…

#EHJCVI 🩺 A new review shows how sex differences influence every stage of valvular heart disease, from aetiology to imaging features and timing of intervention 📊 Multimodality imaging is key to preventing underdiagnosis, especially in women 👉 doi.org/10.1093/ehjci/…

@GillesDreyfus on his TriSCORE #EACVI2025 What is the sweet spot to intervene on the tricuspid valve? Intervene earlier when procedure risk low & anatomic suitability high #echofirst annulus dilates anterior/posterior leaflets(not septal) larger closure area w 🍀 🆚 zipper

Great MMI session on AS Evaluation #EACVI2025 See highlights below. @escardio @EACVIPresident

@MichelleFangCS Fantastic work!!!

We just published a model that does automated data extraction from Cardiac MRI reports. Let AI help make chart reviewing easier and the data collection process faster. Thank you Drs. @DebbieKwonMD & Chen for your mentorship on this project! doi.org/10.1016/j.jocm…

🔥 You don’t want to miss #SCMR2026 in Rio de Janeiro! We’re kicking off the meeting with an unmissable opening plenary by 🗣️ Steven Levine: “The Living Heart: How Digital Twins Are Transforming Cardiovascular Medicine” 🫀 For more informations 👉 bit.ly/4rPbjMC

✨ SCMR is present at #EACVI2025! 🫀 We’re excited to be on site representing SCMR community and sharing upcoming initiatives and events. If you're attending, stop by the booth and say hello! #SCMR #CMR #CardiacImaging

@pswoboda81 @ripley_david @HEARTinMagnet @ColinBerryMD @markcpetrie20 Congrats on designing a very important study with significant implications!! Looking forward to the results and analysis!

"ICA currently recommended (1B) in HFrEF where CAD suspected" Thanks @DebbieKwonMD for promoting CROSS-HF at #EACVI2025

Cross-HF is a pivotal study that will provide important insights to optimize utilization of imaging for HF management!

Treat the valve AND the myocardium when facing severe AS+amyloidosis. Both AVR and tafamidis independently ↓ mortality Dual therapy=best outcomes w/ similar survival to lone AS+AVR. Dual pathology is common (~13%) warranting RCT. tinyurl.com/2zmpht8x Bravo @ThomasTreibel! 👏🏻

Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ. doi.org/10.1093/eurhea… @ESCardio @ESC_Journals #age #5UDMI @johnwmcevoy

#HeartFailure2025 highlighting the prognostic impact of secondary #MR and stressing the role of cardiovascular imaging and Transcatheter therapies on top of #GDMT @iCorGTrias @NAjmoneMarsan @MariannaAdamo1 @EACVIPresident

One of the defining aspects of our fellowship are our accomplished alumni. As a part of our fellowship research day, Dr. Chhatriwalla honored us with a noon conference on advancements in ViV TAVR and bioprosthetic valve fracture! @akcmahi @venumenon10

We’re excited to celebrate our finalists’ research presentations on May 8! We’re also looking forward to welcoming CCF Cards alum @akcmahi back to Cleveland for this special occasion! @venumenon10 @CleClinicHVTI @LarsSvenssonMD @tavrkapadia

@CleClinicCIRC turns 3 years old today and we celebrate all the wonderful research and hard work. I feel honored to work with this talented group of scientists, engineers, and clinicians developing novel CV technologies. @CleClinicHVTI @ClevelandClinic

In the largest cohort of high-risk pts w/ symptomatic native AR undergoing #TAVR w/ JenaValve: 🔹The primary safety & efficacy outcomes met prespecified performance goals -Safety - 26.2% vs 40.5%, p<0.0001 -Efficacy (all-cause mortality) - 8.1% vs. 25%, p<0.0001 #ACC25 🧵1/n